Andrea Lobo, PhD, science writer —

The Cystic Fibrosis Foundation (CFF) has joined the CEO Action for Diversity and Inclusion, adding its name to the more than 2,300 corporate leaders, representing 85 industries, who have pledged to bring greater inclusion and diversity into their workplaces. Organizations with diverse teams perform better, the CFF stated…

The U.S. Food and Drug Administration (FDA) approved the expanded use of Orkambi (lumacaftor/ivacaftor) to treat children starting at 12 months old with cystic fibrosis (CF) who have two copies of the F508del mutation in the cystic…

A poorer adherence to pulmonary therapies does not seem to greatly influence disease severity in patients with cystic fibrosis (CF) who have a nearly normal lung function and good medication adherence rates overall, a study suggests. For this subgroup of patients, CF severity seems to not be associated with…

A defect in an anti-inflammatory pathway called IL-37-SIGIRR contributes to the hyperinflammation seen in lung epithelial cells in patients with cystic fibrosis (CF), a new study suggests. The study shows, for the first time, that a mutated form of the single immunoglobulin interleukin-1 receptor (IL-1R)-related molecule (SIGIRR), named delta…

The clinical outcome of lung infection with Mycobacterium abscessus (M. abscessus) in cystic fibrosis (CF) patients is associated with genetic differences in the bacterium strains, according to a recent study. The study identified virulence factors related to disease severity, and sheds light on the development of novel and more effective…